NEWS RELEASE
Office of Maryland Attorney General J. Joseph Curran, Jr.


October 5, 2001 Media Inquiries: Sean Caine 410-576-6357

MARYLAND TO RECEIVE OVER $327,000 FROM DRUG COMPANY

Attorney General J. Joseph Curran Jr. announced today that he, in conjunction with the National Association of Medicaid Fraud Control Units has reached an agreement in principle with TAP Pharmaceutical Products, Inc. to pay $56.7 million to the state Medicaid programs for damages caused by TAPís marketing practices for its drug Lupron, used for the treatment of prostrate cancer. As part of the settlement, the State of Maryland will recover $327,693.67 in restitution and penalties. The agreement in principle involves all 50 states plus the District of Columbia.

This state settlement was reached in conjunction with a federal settlement negotiated by the United States Attorneyís Office in Boston. Under the federal agreement, TAP will plead guilty to charges of conspiracy to violate the Prescription Drug Marketing Act, and enter a civil settlement to pay damages to Medicare and other federally funded health care programs. As part of the federal settlement, TAP will pay the federal government $524.3 million as well as a substantial criminal fine.

These settlements are the culmination of a lengthy investigation into TAPís marketing practices, which centered around TAPís provision of free dosages of Lupron to physicians and other providers, knowing that these providers would bill these free dosages to health care insurers, including Medicaid and Medicare. When TAP failed to include the free Lupron in the calculation of its "best price" as required under the federal Medicaid drug rebate program, the State of Maryland alleges that the Medicaid programs received lower rebate amounts than due.

A second marketing practice addressed by this settlement involved TAPís inflation of "Average Wholesale Price." Medicare and most state Medicaid programs base pharmaceutical reimbursements on "AWP." By inflating "AWP," the State of Maryland alleges that TAP created an economic incentive for physicians to prescribe its product, because the physician kept the "spread" between the true purchase price and the reported "AWP." This resulted in damage to the various Medicaid programs by causing inflated reimbursement to physicians and others who used TAPís products.

As part of the agreement in principle with the states, TAP will be required to report accurate pricing information to the state Medicaid programs as well as the commercial price reporting services that provide pricing information to the states. Additionally, TAP will cooperate with the states in investigating other health care providers, including physicians, who have damaged the Medicaid programs by taking advantage of TAPís marketing schemes.

###